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Abstract The purpose of this study was to estimate the
burden of osteoporotic fractures beyond the hospitalization
period covering up to the first year after the fracture. This
was a prospective, 12-month, observational study including
patients aged C65 years hospitalized due to a first low-
trauma hip fracture, in six Spanish regions. Health resource
utilization (HRU), quality of life (QoL) and autonomy were
collected and total costs calculated. Four hundred and
eighty seven patients (mean ± SD age 83 ± 7 years, 77 %
women) were included. Twenty-two percent of patients
reported a prior non-hip low-trauma fracture, 16 % were
receiving osteoporotic treatment at baseline, and 3 % had
densitometry performed (1.8 % T-score B-2.5). Sixteen
percent of patients died (women 14 %; men 25 %;
p = 0.0011) during the first year. Mean hospital stay was
11.8 ± 7.9 days and 95.1 % of patients underwent surgery.
Other relevant HRUs were: outpatient visits in 78 % of
patients (mean 9.2 ± 9.7); walking aids, 58.7 %; rehabil-
itation facilities, 35.5 % (28.7 ± 41.2 sessions); and for-
mal and informal home care, 22.2 % (49.6 ± 72.2 days)
and 53.4 % (77.1 ± 101.0 h), respectively. Mean direct
cost was €9690 (95 % confidence interval: 9184–10,197)
in women and €9019 (8079–9958) in men. Main cost dri-
vers were: first hospitalization episode (women €7067
[73 %]; men €7196 [80 %]); outpatient visits (€1323
[14 %]; €997 [11 %]); and home care (€905 [9 %]; €767
[9 %]). QoL and autonomy showed a marked decrease
during hospitalization, not entirely recovered at 12 months
(p\ 0.05 vs. baseline for EQ-5D, Harris hip score and
modified Barthel index). In a Spanish setting, osteoporotic
hip fractures incur a high societal and economic cost,
mainly due to the first hospitalization HRU, but also due to
subsequent outpatient visits and home care.
Keywords Osteoporosis  Hip fracture  Quality of life 
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Introduction
Osteoporosis is characterized by compromised bone
strength predisposing to an increased risk of fracture [1]. In
the year 2000, there were approximately 9.0 million
osteoporotic fractures with the greatest number occurring
in Europe (34.8 %) [2]. Osteoporosis and resulting frac-
tures have significant consequences on human health, QoL
and societal burden [2]. Hip fractures place a high burden
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for patients and healthcare systems due to the advanced age
of affected patients, the need for complex surgeries and the
high impact on patients’ mobility [3]. However, this burden
is systematically underestimated since usually only the
admission period is considered. Hip fractures are also
associated with a high mortality both during hospitalization
[3] and following discharge [4].
In Spain, the annual incidence of hip fractures in
patients aged C65 years has been estimated at 36,000
(90.5 % of all hip fractures) [3], and it is continuously
increasing due to an ageing population (increase of 18 %
between 1997 and 2008 [5]). There is limited evidence
quantifying the burden of hip fractures at the Spanish
national and regional levels, taking into account the dif-
ferences between regional Health Systems, with only three
retrospective chart review studies [6–8] and one study
extrapolating data from two clinical trials available [9].
Therefore, there is a need for an updated and reliable
estimate of the cost of an osteoporotic hip fracture in Spain
to help regions in their decision making.
The primary objective of this study was to estimate
health resource utilization (HRU) and related costs asso-
ciated with osteoporotic hip fractures over 12 months in
patients of 65 years of age or older in Spain. The secondary
objectives were: to describe patients’ characteristics,
health-related quality of life (HRQoL), physical function-
ing and autonomy/dependency from others and the cir-
cumstances leading to the hip fracture.
Patients and Methods
The PROA (PRospective Observational study on burden of
hip frActures in Spain) was a prospective, 12-month,
observational study. Patients C65 years admitted to hos-
pital due to a first osteoporotic hip fracture (defined as
fracture due to a low impact or falling from a standing
height or less or any mild or moderate trauma not resulting
from a fall [10]) were included. The exclusion criteria
were: hip fracture secondary to severe trauma (defined as a
fall from a height higher than that of a stool, chair or first
rung of a ladder, or severe trauma other than a fall), con-
current non-hip fracture, malignancy or primary bone dis-
ease, and participation in an interventional trial in the last
6 months. The protocol was approved by an independent
ethics committee, and all patients gave written informed
consent before enrolment. For patients who suffered from
cognitive impairment, informed consent was given by a
legal representative and patient-reported data were pro-
vided by the representative at each visit.
The study was conducted in six regions (Andalusia,
Basque Country, Catalonia, Galicia, Madrid and Valencia)
including small (\200 beds), medium (200–500 beds) and
large hospitals ([500 beds). Data were collected at baseline
(first admission to hospital), hospital discharge and 4 and
12 months post-fracture. At baseline, the following vari-
ables were collected: demographic data, fracture risk fac-
tors, comorbidities (Charlson comorbidity index [11, 12])
and circumstances of the fall/event leading to the hip
fracture. Fracture-associated HRUs were collected at all
visits: inpatient care (length of hospital stay, imaging, type
of surgery and/or prosthesis, treatment of complications);
re-hospitalizations; ambulatory care (number and type of
outpatient visits; physician or nurse), home visits (occu-
pational therapist, physician and nurse) and/or telephone
support; rehabilitation (number of physiotherapy sessions);
walking aids; visits to emergency departments; and formal
(social workers, nursing home stay, rehabilitation facility
stay) and/or informal home care (relatives or paid worker).
HRQoL (EuroQoL-5 dimensions [EQ-5D] questionnaire
[13, 14]) and patient autonomy (modified Barthel index
[15] and Harris hip score [16]) were also collected at all
visits (retrospectively at baseline, in reference to the status
prior to the fracture). HRUs at the time of death were not
collected.
Statistical Analysis
The Spanish Healthcare System perspective has been
applied, except for the informal home care resources.
Unitary costs were obtained from the eSalud database
(http://www.oblikue.com/bddcostes) and adjusted to 2012
values. Mean annual costs and 95 % confidence intervals
(CI) were calculated (using 1000 bootstrap samples). The
cost of informal home care was estimated by applying
the official national minimum wage in Spain. Data
regarding home support (formal or informal) before the
fracture were asked to the patient or proxy responder
(e.g. caregiver or relative) at the beginning of the study.
The cost associated with hip fracture was computed as
the difference between that of care provided before and
after the fracture, as utilized in previous studies [17].
Descriptive analyses were provided for each variable
at all the study visits. Changes in continuous variables
over time were analysed using paired T tests. Differences
between subgroups of patients were tested using Stu-
dent’s T tests, Mann–Whitney or Chi-squared tests, as
applicable. Time to death was summarized using Kaplan–
Meier methodology. Survival differences between men/-
women were evaluated using a univariate Cox regression
model. Statistical analyses were performed with the SAS
statistical software package (SAS Institute, Inc, Cary,
NC).
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Results
Baseline Characteristics and Circumstances
of the Fall Leading to the Hip Fracture
A total of 487 patients (77 % women) were included in 28
Spanish hospitals between 31 March 2011 and 29 June
2012. Of them, 357 (73.3 %) were followed up during
12 months. Most premature discontinuations (77/130,
59.2 %) were due to death.
Table 1 shows the main characteristics of the study
cohort. The mean (SD) age of patients with a first osteo-
porotic hip fracture was similar for both sexes: 83.2 (6.6)
and 81.1 (7.0) for women and men, respectively. Around
one-third of patients had at least one previous non-hip
fracture, of which 59.7 % had been reported as low impact
fractures. A total of 15.6 % of patients were receiving
osteoporotic treatment at the time of the fracture occur-
rence, and only 3 % had undergone bone densitometry
testing (1.8 % had BMD T-score B-2.5).
The majority of patients lived with a partner or family
member sharing their own home (61.2 %), with 19.1 %
living alone, 11.3 % living in a nursing home and 8.2 %
living in a relative’s home. The circumstances of the fall
leading to the hip fracture were similar between men and
women. Most falls occurred inside, in the morning and in
autumn or summer. Approximately one-third (35.1 %) of
subjects were receiving medications that increase the risk
of falls (Table 1).
During the follow-up, 18 (3.7 %) patients had at least
one new fracture (total of 19 fractures, 95 % osteoporotic
origin).
Health-Related Quality of Life and Patient
Autonomy
The HRQoL results and changes in patient autonomy
showed a statistically significant decrease during hospital-
ization and up to 12 months after (Table 2). Furthermore,
patients living independent of caregivers or family mem-
bers decreased after 12 months compared to baseline (36
vs. 77, respectively) (Online Resource 1).
Health Resource Utilization
HRU was high, both during the first hospitalization and at
12-month follow-up. The results were similar across gen-
ders, except for re-hospitalizations which were more fre-
quent among women versus men (6.4 vs. 3.6 %).
The 95.1 % of patients underwent surgery, mainly
intramedullary nail osteosynthesis in women and partial
prosthesis in men. Mean length of hospital stay during first
hospitalization was 11.8 ± 7.9 days (Tables 3, 4).
There was a large number of outpatient visits (median:
6.0, range: 1–75), use of rehabilitation facilities (median:
15 sessions, range: 1–320), walking aids (58.7 % of
patients) and home care (22.2 % of patients with formal
care [median of 25 days] and 53.4 % with informal care
[median of 35 h]) (Table 3). Seventy-seven patients
(15.8 %) required both formal and informal home care.
Direct Medical Costs
Mean total cost during the first year was €9690 (95 % CI:
9184–10,197) in women and €9019 (8079–9958) in men,
with no significant differences between genders except for
the cost of re-hospitalizations (Table 4).
The main cost determinant was first hospitalization
(€7067 and €7196 in women and men, respectively), fol-
lowed by ambulatory care and home care (Table 4).
Subgroup Analyses by Size of Centre
When HRU was analysed by size of centre, large centres
showed longer hospital stays (mean of 13.8 days versus
10.2 and 9.0 in small and medium centres, respectively).
However, after discharge, patients treated at small centres
had more outpatient visits (mean of 10.0 [in all patients]
versus 6.3 and 6.5 in medium and large centres), rehabil-
itation sessions (mean of 17.1 vs. 10.7 and 7.4) and formal
home care (mean of 16.6 days vs. 10.5 and 9.3), but less
informal care (mean of 29.1 h vs. 48.6 and 41.5 in medium
and large centres).
Mortality
During the 12-month follow-up, 15.8 % of patients died,
53 % of them within the first 3 months (Fig. 1). Mortality
was significantly higher in men than in women (24.1 vs.
13.4 %, respectively, p = 0.0011).
Discussion
The PROA constitutes the first large, multicentre,
prospective study specifically designed to provide esti-
mates on the cost of osteoporotic hip fractures in Spain.
Overall, the socio-demographic characteristics of our
cohort were comparable to those from similar studies
conducted in Belgium [18], Sweden [19] or the UK [20].
Nevertheless, there were some notable differences between
this and other national studies. The mean age of this cohort
was similar for both sexes and higher than that reported
previously, most likely due to the comparatively higher
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Table 1 Baseline characteristics and osteoporosis risk profile of patients with a first osteoporotic hip fracture in Spain
Women (N = 375) Men (N = 112) Total (N = 487)
Age, years, mean ± SD 83.2 (6.6) 83.1 (7.0) 83.2 (6.7)
C75 years 339 (90.4) 100 (89.3) 439 (90.1)
Sex, woman – – 375 (77.0)
Type of centre
Small 67 (17.9) 26 (23.2) 93 (19.1)
Medium 101 (26.9) 37 (33.0) 138 (28.3)
Large 207 (55.2) 49 (43.8) 256 (52.6)
Alcohol intake 21 (5.6) 26 (23.2) 47 (9.6)
Active smoking 7 (1.9) 11 (9.8) 18 (3.7)
Body mass index (kg/m2)
\18.5 8 (2.1) 0 (0) 8 (1.6)
18.5–\25.0 159 (42.4) 51 (45.5) 210 (43.1)
25.0–\30.0 112 (29.9) 39 (34.8) 151 (31.0)
C30.0 58 (15.5) 12 (10.7) 70 (14.4)
Missing 38 (10.1) 10 (8.9) 48 (9.9)
Diagnosis of osteoporosis established by densitometry (T-score B-2.5) 8 (2.1) 1 (0.9) 9 (1.8)
T-score not available 362 (96.5) 110 (98.2) 472 (96.9)
Secondary osteoporosisa 10 (2.7) 4 (3.6) 14 (2.9)
Prior non-hip fracture 144 (38.4) 37 (33.3) 181 (37.2)
Prior non-hip fracture by low impact trauma 88 (23.5) 20 (17.9) 108 (22.2)
Time since last fracture, months, median (Q1, Q3)b 42.1 (18.7, 109.5) 75.8 (28.2, 163.7) 43.0 (20.4, 123.4)
Location of previous fracturesc
Wrist 50 (13.3) 10 (8.9) 60 (12.3)
Shoulder 24 (6.4) 4 (3.6) 28 (5.7)
Spine 16 (4.3) 7 (6.3) 23 (4.7)
Upper arm 17 (4.5) 2 (1.8) 19 (3.9)
Other 67 (17.9) 16 (14.3) 87 (17.9)
Prior osteoporotic treatment 70 (18.7) 6 (5.4) 76 (15.6)
Other risk factors for fracture
Parental hip fracture 21 (5.6) 9 (8.0) 30 (6.2)
Use of glucocorticoids 22 (5.9) 5 (4.5) 27 (5.5)
Diagnosis of rheumatoid arthritis 13 (3.5) 1 (0.9) 14 (2.9)
Main comorbidities
Diabetes 75 (20.0) 24 (21.4) 99 (20.3)
Dementia 44 (20.5) 18 (16.1) 95 (19.5)
Cerebrovascular disease 54 (14.4) 28 (25.0) 82 (16.8)
Congestive heart failure 45 (12.0) 13 (11.6) 58 (11.9)
Peripheral vascular disease 48 (12.8) 8 (7.1) 56 (11.5)
Chronic pulmonary disease 22 (5.9) 26 (23.2) 48 (9.9)
Myocardial infarction 29 (7.7) 19 (17.0) 48 (9.9)
Any tumour 13 (3.5) 8 (7.1) 21 (4.3)
Moderate or severe renal disease 13 (3.5) 8 (7.1) 21 (4.3)
Charlson index, mean (SD)d 1.8 (1.1) 2.4 (1.7) 1.9 (1.3)
Hip fracture result of a fall 373 (99.5) 110 (98.2) 483 (99.2)
Living arrangements prior to the fall
Alone in own home 82 (21.9) 11 (9.8) 93 (19.1)
Partner/family member sharing own home 219 (58.4) 79 (70.5) 298 (61.2)
Nursing home 40 (10.7) 15 (13.4) 55 (11.3)
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proportion of patients aged 75 years old or above
[3, 21, 22]. Furthermore, while the proportion of patients
sharing their own home/living alone was similar to that of
the Spanish population, the proportion of patients living in
a nursing home was greater in this cohort compared to
national averages [23]. Lastly, the prevalence of prior
vertebral fractures was extremely low (4.7 %) compared to
the estimated 20 % in the Spanish population of similar
age, most likely due to the fact that in this study only
fractures that were documented in the patient’s medical file
were collected as opposed to the acquisition of X-rays of
the thoracic and lumbar spine using the Genant method
[24, 25]. That being said, the similar prevalence of verte-
bral fractures previously registered in the patient’s file
(1.2–4.3 %) reflects the underdiagnosis of these fractures in
the daily practice [24].
Table 1 continued
Women (N = 375) Men (N = 112) Total (N = 487)
Relatives home 33 (8.8) 7 (6.3) 40 (8.2)
Patient alone at the time of a fall 172 (45.9) 38 (33.9) 210 (43.1)
Where fall happened
Inside 294 (78.4) 84 (75.0) 378 (77.6)
Outside 79 (21.1) 26 (23.2) 105 (21.6)
Missing 2 (0.5) 2 (1.8) 4 (0.8)
If fall happened outside, weather conditions
Dry 68 (18.1) 21 (18.8) 89 (18.3)
Wet 10 (2.7) 4 (3.6) 14 (2.9)
Icy 1 (0.3) 1 (0.9) 2 (0.4)
Season when the fall took place
Winter 59 (15.7) 19 (17.0) 78 (16.0)
Spring 74 (19.7) 28 (25.0) 102 (20.9)
Summer 103 (27.5) 28 (25.0) 131 (26.9)
Autumn 137 (36.6) 35 (31.3) 172 (35.3)
Missing 2 (0.5) 2 (1.7) 4 (0.8)
Patient receiving medications that increase the risk of falls 136 (36.3) 35 (31.3) 171 (35.1)
Data are number of patients (percentage) except when otherwise indicated; a defined as conditions such as type I diabetes, osteogenesis
imperfecta, untreated long-standing hyperparathyroidism, hypogonadism or premature menopause, chronic malnutrition, or malabsorption and
chronic liver disease; b calculated at enrolment in patients with a previous non-hip fracture; c subjects could have multiple previous fractures at
different locations; subjects with more than one fracture in the same location were counted only once in that location; d valid N = 256/86/342 for
women, men and overall, respectively; Q1 = 25th percentile; Q3 = 75th percentile; SD standard deviation
Table 2 Changes in health-related quality of life and patient autonomy during the 12-month follow-up
Baseline (prior
to the fracture)
Discharge 4 months 12 months
EQ-5D, health state index, mean (SD)a 0.57 (0.39) 0.04 (0.39)* 0.47 (0.41)* 0.53 (0.41)*
Valid N 454 446 303 318
Change from baseline, mean (95 % CI) -0.54 (-0.58 to -0.50) -0.11 (-0.16 to -0.06) -0.06 (-0.11 to -0.01)
Harris hip score, mean (SD)b 74.9 (19.6) 46.6 (14.6)* 64.7 (17.9)* 69.1 (18.9)*
Valid N 353 341 223 244
Change from baseline, mean (95 % CI) -28.3 (-30.4 to -28.3) -9.9 (-12.6 to -7.2) -7.1 (-9.7 to -4.5)
Modified Barthel index, mean (SD)c 77.5 (26.9) 40.4 (24.3)* 66.4 (31.4)* 70.4 (31.1)*
Valid N 441 433 287 306
Change from baseline, mean (95 % CI) -37.3 (-39.5 to -35.1) -12.2 (-14.9 to -9.5) -9.8 (-12.5 to -7.1)
a The health state index score ranges between -0.594 and 1.0. A higher score indicates a more preferred health status, b Harris hip score ranges
between 0 and 100. A higher score indicates better function, c the modified Barthel index ranges between 0 and 100. A higher score indicates
better function
* p\ 0.05 versus baseline
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Table 3 Health resource utilization
Women (N = 375) Men (N = 112) Total (N = 487)
First hospitalization
Hospital stay, days, mean (SD) 11.8 (7.9) 11.9 (8.1) 11.8 (7.9)
Median (min–max) 10.0 (1–69) 10.0 (2–54) 10.0 (1–69)
Geriatric ward, % 0.5 1.7 0.8
Days, mean (SD) 5.0 (1.4) 12.0 (2.8) 8.5 (4.4)
Intensive care, % 26.7 22.3 25.7
Days, mean (SD) 1.0 (0.2) 1.5 (2.0) 1.1 (0.9)
Orthopaedic ward, % 99.2 98.2 99.0
Days, mean (SD) 11.4 (7.7) 11.4 (8.0) 11.4 (7.8)
Other wards, % 2.1 0.8 3.7
Days, mean (SD) 2.9 (5.3) 1.7 (1.6) 2.2 (3.6)
Surgical intervention, % 95.7 92.9 95.1
Intramedullary nail osteosynthesis 45.3 31.3 42.1
Sliding screw osteosynthesis 17.6 17.9 17.7
Partial prosthesis 28.5 36.6 30.4
Total prosthesis 4.8 8.0 5.5
Imaging 96.8 99.1 97.3
CT, % 5.9 6.2 6.0
Num. times used, mean (SD) 1.2 (0.5) 1.0 (0) 1.2 (0.5)
Ultrasound, % 4.3 4.5 4.3
Num. times used, mean (SD) 1.1 (0.3) 1.4 (0.9) 1.1 (0.5)
X-ray, % 96.8 99.1 97.3
Num. times used, mean (SD) 4.0 (1.8) 4.2 (1.7) 4.0 (1.8)
Other proceduresa, % 0.5 58.9 49.9
Num. times used, mean (SD) 5.8 (3.5) 6.4 (5.0) 5.9 (3.9)
Emergency room visit prior to hospitalization, % 86.9 84.8 86.4
12-month follow-up
Re-hospitalizations, % 6.4 3.6 5.7
Hospital stay, days, mean (SD) 16.2 (13.9) 5.8 (4.5) 14.7 (13.4)
Median (min–max) 12.5 (2–56) 4.5 (2–12) 10.5 (2–56)
Imaging, % 5.9 3.6 5.3
Surgical intervention, % 0.8 0 0.6
Intramedullary nail osteosynthesis 0.5 0 0.4
Partial prosthesis 0.3 0 0.2
Other proceduresa, % 4.3 3.6 4.1
Ambulatory care
Outpatient visits, % 81.3 67.0 78.0
Number of visits, mean (SD) 9.1 (9.5) 9.4 (10.9) 9.2 (9.7)
Median (min–max) 6.0 (1–75) 6 (1–58) 6 (1–75)
Nurse at health centre visits, % 31.7 31.2 31.6
Number of visits, mean (SD) 3.2 (4.9) 1.9 (1.4) 2.9 (4.4)
Nurse’s home visits, % 39.5 33.0 38.0
Number of visits, mean (SD) 5.8 (7.1) 7.1 (8.5) 6.0 (7.4)
Physician at health centre visits, % 38.7 38.4 38.6
Number of visits, mean (SD) 3.0 (2.4) 2.8 (2.3) 3.0 (2.4)
Specialist, % 61.9 57.1 60.8
Number of visits, mean (SD) 3.1 (2.5) 2.8 (3.0) 3.0 (2.6)
Physician’s home visits, % 29.1 15.2 25.9
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Of note, almost all first osteoporotic hip fractures occur-
red in individuals at high risk of fracture, although only a low
percentage were previously diagnosed and treated for
osteoporosis. The treatment gap (patients eligible for treat-
ment not receiving any drug) for osteoporosis in 2010 was
estimated between 57 % (women) and 59 % (men) in the
European Union [1]. In Spain, this gap was 25 and 20 %, but
in our cohort it could be [30 %, according to the high
prevalence of prior osteoporotic fractures and an important
underuse of osteoporotic treatments in the recent years [26].
Similarly to previous studies [18, 19, 27], HRU during
hospitalization was high, mainly related to a long hospital
stay and to the need for surgery. The mean hospital stay
(12 days) was similar than that reported in local studies [7]
and in a previous analysis of Minimum Basic Data Set
between 1997 and 2008 (13 days) [28], but much lower
than the 23-day length reported in 1989 [8]. Health
resource utilization in the first year following hospital
discharge was similar to the observed in Sweden or Bel-
gium [18, 19, 27]. The proportion of patients with re-
Table 3 continued
Women (N = 375) Men (N = 112) Total (N = 487)
Number of visits, mean (SD) 3.4 (3.8) 4.6 (4.3) 3.6 (3.9)
Rehabilitation facility, % 36.3 33.0 35.5
Number of sessions, mean (SD) 28.5 (43.2) 29.6 (33.5) 28.7 (41.2)
Median (min–max) 16 (1–320) 14 (1–128) 15 (1–320)
Health centre, % 14.7 11.6 14.0
Number of sessions, mean (SD) 27.4 (25.3) 36.8 (38.5) 29.2 (28.2)
Home, % 24.5 25.9 24.8
Number of sessions, mean (SD) 25.7 (41.1) 21.3 (23.9) 24.7 (37.6)
Imaging, % 4.0 1.8 3.5
Num. times used, mean (SD) 6.5 (4.7) 6.0 (5.7) 6.4 (4.6)
Other proceduresa, % 2.4 1.8 2.3
Num. times used, mean (SD) 2.0 (1.7) 2.5 (2.1) 2.1 (1.6)
Ambulance use, % 53.3 37.5 49.7
Num. times used, mean (SD) 5.0 (10.6) 4.0 (4.4) 4.8 (9.8)
Visits to emergency room, % 16.0 14.3 15.6
Num. times used, mean (SD) 1.9 (2.2) 1.4 (0.7) 1.8 (2.0)
Walking aids, % 60.3 53.6 58.7
Walker 49.9 44.6 48.7
Wheelchair 16.5 14.3 16.0
Home care
Formal, % 23.7 17.0 22.2
Days, mean (SD) 47.1 (66.7) 61.6 (95.1) 49.6 (72.2)
Median (min–max) 26.5 (1–411) 47.0 (1–618) 25.1 (1–411)
Care from social workers, % 4.5 5.4 4.7
Days, mean (SD) 6.6 (8.2) 5.8 (2.8) 6.4 (7.2)
Nursing home, % 8.8 4.5 7.8
Days, mean (SD) 56.7 (63.5) 110.0 (96.9) 63.7 (69.6)
Rehabilitation facility, % 15.5 10.7 14.4
Days, mean (SD) 38.1 (38.0) 48.7 (45.3) 39.9 (39.2)
Informal, % 56.5 42.9 53.4
Hours, mean (SD) 78.0 (103.7) 73.1 (89.3) 77.1 (101.0)
Median (min–max) 35 (1–672) 38 (2–336) 35 (1–672)
Cared by relatives, % 49.3 39.3 47.0
Hours, mean (SD) 64.7 (81.7) 61.8 (79.4) 64.1 (81.1)
Paid worker, % 24.5 16.1 22.6
Hours, mean (SD) 49.6 (69.9) 44.0 (67.3) 48.7 (69.2)
Mean (SD) number of each HRU calculated among those patients reporting 1 or more
a Mainly blood tests; CT computed tomography, SD standard deviation
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hospitalization related to the hip fracture was very low in
comparison with previous studies that collected all type of
hospitalizations (17–30 %) [29, 30].
The cost obtained for the first hospitalization (*€7000)
was consistent with the disease-related groups applicable to
hip fracture in Spain (210, 211, 236, 558 and 818, cost:
Table 4 Direct medical costs
during the first year after a first
osteoporotic hip fracture
Mean € (95 % CI) Women (N = 375) Men (N = 112)
Total direct cost 9690 (9184, 10,197) 9019 (8079, 9958)
First hospitalization
First hospitalization 7067 (6733, 7401) 7196 (6522, 7870)
Hospital stay 4796 (4469, 5122) 4856 (4240, 5472)
Geriatric ward 11 (0, 26) 88 (0, 211)
Intensive care 154 (127, 181) 184 (66, 301)
Orthopaedic ward 4631 (4311, 4950) 4584 (3964, 5205)
Surgical intervention 2064 (1997, 2131) 2128 (1969, 2288)
Intramedullary nail osteosynthesis 795 (706, 884) 545 (393, 697)
Sliding screw osteosynthesis 401 (312, 490) 401 (239, 562)
Partial prosthesis 691 (580, 803) 887 (667, 1106)
Total prosthesis 177 (97, 257) 296 (108, 484)
Imaging 89 (83, 94) 96 (87, 106)
Computed tomography 6 (3, 8) 5 (1, 9)
Ultrasound 4 (2, 5) 5 (0, 10)
X-ray 80 (76, 84) 87 (80, 94)
Emergency room visit prior to hosp. 118 (114, 123) 115 (106, 125)
12-month follow-up
Re-hospitalizationb 395 (173, 617) 59 (0, 120)
Ambulatory care 1323 (1119, 1528) 997 (753, 1241)
Outpatient visits 329 (291, 367) 281 (204, 359)
Nurse at health centre visits 16 (11, 21) 10 (6, 13)
Nurse’s home visits 73 (56, 91) 75 (40, 110)
Physician at health centre visits 56 (46, 66) 50 (33, 68)
Specialist 122 (106, 138) 104 (72, 135)
Physician’s home visits 62 (46, 78) 43 (16, 70)
Rehabilitation facility 284 (191, 376) 258 (142, 373)
Health centre 48 (32, 65) 52 (12, 91)
Home 235 (148, 323) 206 (100, 313)
Imaging 6 (2, 10) 3 (0, 8)
Ambulance use 486 (336, 635) 269 (157, 382)
Visits to emergency room 42 (26, 57) 29 (14, 44)
Walking aids 177 (148, 207) 157 (104, 210)
Walker 55 (49, 62) 49 (37, 60)
Wheelchair 122 (92, 152) 109 (55, 162)
Home care, mean use 905 (690, 1121) 767 (285, 1250)
Formal 603 (397, 810) 563 (116, 1009)
Care from social workers 18 (5, 31) 18 (3, 35)
Nursing home 258 (129, 387) 254 (-30, 538)
Rehabilitation facility 327 (213, 441) 290 (74, 506)
Informal 302 (236, 368) 205 (114, 296)
Cared by relatives 162 (128, 196) 123 (68, 178)
Paid worker 140 (93, 188) 81 (15, 148)
CI confidence interval, Hosp hospitalization
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€2684-€14,878) [28]. This cost increased by 70 % between
1997 and 2008 in Spain (€4909 to €8365) [8, 28], probably
related to the increase in mean age (2 years) and comor-
bidities of the patients, and the increase in the number of
surgical interventions (86 % in 1997) [28].
The total cost in the first year after the first fracture
(*€9000) is higher than that reported in Spain after a non-
fatal stroke (€4638) but lower than after a myocardial
infarction (€19,277) [31]. Our study suggests that, if only
the first hospitalization is considered, one-fourth of the
total annual cost of a hip fracture might be underestimated.
Compared to other European countries, the cost seems
to be approximately a 25 % lower (€13,470 in Belgium;
€14,221 in Sweden). In a UK cohort, the cost was slightly
lower (€7536) [20], but in that study the costs associated
with rehabilitation services and home care were not taken
into account.
Mortality was high, especially in males (24.1 %). In
both genders, mortality rates were almost three times
higher compared to the annual mortality rate of Spanish
general population of a similar age (7.4 and 4.5 %,
respectively, in males and females of 80–84 years old)
[32].
Prior to the fracture, the HRQoL was similar to that
reported in Spanish population aged C85 [33], but it
showed a marked worsening during the hospital stay and
was not entirely resolved after 12 months, highlighting the
long-term burden of the hip fracture.
Our study has some limitations. The similarity in age
between sexes combined with the high proportion of
patients aged 75 years old or above may limit the gener-
alizability of these results to all patients with osteoporotic
hip fractures in Spain aged C65 years old. The total cost
may have been underestimated due to the inability of the
study to collect the HRU at the time of death, inherent to
the nature of observational design. Patient-reported HRU
after hospital discharge, such as visits to the general
practitioner, emergency room visits or re-hospitalizations,
may have been underestimated due to the inability of the
patient to recall information, leading to potential
misclassification.
Strengths of our study include the large sample size and
the geographically distributed recruitment, which ensures
that it represents the regional diversity of Spain. Also, the
prospective follow-up allowed a more comprehensive data
collection on both the economic and humanistic burden of
the condition not routinely included in patients’ medical
records.
In conclusion, in a Spanish setting, osteoporotic hip
fractures incur a high societal and economic cost, mainly
due to the high HRU during the first hospitalization, but
also due to subsequent outpatient visits and home care. Hip
fractures were also associated with a high mortality of
approximately one in six patients during the first year. The
high prevalence of known risk factors and the low number
of patients receiving prophylactic treatment highlight the
undertreatment of this population, typically women older
than 75 years with prior fractures, several comorbidities
such as diabetes or dementia, and receiving medications
that increase the risk of falls. By comparison, men in this
study cohort not only received less osteoporosis follow-up
prior to the hip fracture, but also exhibited a greater fre-
quency of risk factors such as smoking and excessive
alcohol consumption. Together, these results reflect the
need for improving the diagnostic and therapeutic man-
agement of osteoporosis in Spain.
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